Evidence map›Paper›PMID 25996296›Full record

ArticleCell death & disease2015

Necrosis- and apoptosis-related Met cleavages have divergent functional consequences.

R Montagne, M Berbon, L Doublet, N Debreuck, A Baranzelli, H Drobecq, C Leroy, N Delhem, H Porte, M-C Copin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

R MontagneCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
M BerbonCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
L Doublet1] CNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France [2] Département de Cancérologie Générale, CLCC Oscar Lambret, Université de Lille, 3 rue Fréderic Combemale, Lille 59020, France.
N DebreuckCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
A BaranzelliCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
H DrobecqCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
C LeroyCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
N DelhemCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
H PorteService de Chirurgie Thoracique, Centre Hospitalier Régional Universitaire de Lille, Université de Lille, Lille, France.
M-C Copin1] CNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France [2] Institut de Pathologie, Centre Hospitalier Régional Universitaire de Lille, Université de Lille, Avenue Oscar Lambret, Lille 59037, France.
E DansinDépartement de Cancérologie Générale, CLCC Oscar Lambret, Université de Lille, 3 rue Fréderic Combemale, Lille 59020, France.
A FurlanCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
D TulasneCNRS UMR 8161, Institut de Biologie de Lille-Institut Pasteur de Lille, Université de Lille, SIRIC ONCOLille, Lille 59021, France.
Onco Lille · FRInstitut de Biologie de Lille · FRCentre Hospitalier Universitaire de Lille · FRCentre Oscar Lambret · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upon activation by its ligand hepatocyte growth factor/scatter factor, the receptor tyrosine kinase Met promotes survival, proliferation, and migration of epithelial cells during embryogenesis. Deregulated Met signaling can also promote cancer progression and metastasis. Met belongs to the functional family of dependence receptors whose activity switches from pro-survival to pro-apoptotic during apoptosis upon caspase cleavage. Although apoptosis resistance is a hallmark of cancer cells, some remain sensitive to other cell death processes, including necrosis induced by calcium stress. The role and fate of Met during necrotic cell death are unknown. Following treatment with calcium ionophores, cell lines and primary cells undergo necrosis, and the full-length Met receptor is efficiently degraded. This degradation is achieved by double cleavage of Met in its extracellular domain by a metalloprotease of the A disintegrin and metalloproteinase (ADAM) family and in its intracellular domain by calpains (calcium-dependent proteases). These cleavages separate the Met extracellular region from its kinase domain, thus preventing Met activity and its potential pro-survival activity. Although the intracellular fragment is very similar to the fragment generated by caspases, it displays no pro-apoptotic property, likely because of the presence of the last few amino acids of Met, known to inhibit this pro-apoptotic function. The fragments identified here are observed in lung tumors overexpressing the Met receptor, along with fragments previously identified, suggesting that proteolytic cleavages of Met are involved in its degradation in tumor tissues. Thus, Met is a modulator of necrosis, able to protect cells when activated by its ligand but efficiently degraded by proteolysis when this process is engaged.

Indexed as

ADAM ProteinsAnimalsApoptosisCalciumCalpainCaspasesCell Line, TumorCell MovementCell ProliferationCell SurvivalEnzyme ActivationEpithelial CellsHEK293 CellsHepatocyte Growth FactorHumansIonomycinADAM ProteinsCalciumCalpainCaspasesHepatocyte Growth FactorHGF protein, humanIonomycinMET protein, humanProto-Oncogene Proteins c-metRNA, Small Interfering

Identifiers

PMID25996296
PMCPMC4669710
OpenAlexW429537055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.